Nan Fung Group Holdings’s Acadia Pharmaceuticals ACAD Stock Holding History

Nan Fung Group Holdings’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.61M	Hold	102,984	–	–	1.98%	14
2026 Q1	$2.29M	Hold	102,984	–	–	1.89%	13
2025 Q4	$2.75M	Hold	102,984	–	–	2.46%	12
2025 Q3	$2.2M	Hold	102,984	–	–	3.69%	11
2025 Q2	$2.22M	Hold	102,984	–	–	3.5%	11
2025 Q1	$1.71M	Hold	102,984	–	–	1.4%	23
2024 Q4	$1.89M	Hold	102,984	–	–	1.62%	20
2024 Q3	$1.58M	Hold	102,984	–	–	1.36%	23
2024 Q2	$1.67M	Hold	102,984	–	–	1.79%	19
2024 Q1	$1.9M	Buy	102,984 +73,000	+243%	+$1.81M	1.76%	17
2023 Q4	$939K	Hold	29,984	–	–	0.58%	23
2023 Q3	$625K	Hold	29,984	–	–	0.51%	25
2023 Q2	$718K	Hold	29,984	–	–	0.46%	26
2023 Q1	$564K	Hold	29,984	–	–	0.38%	32
2022 Q4	$477K	Hold	29,984	–	–	0.33%	30
2022 Q3	$491K	Hold	29,984	–	–	0.31%	26
2022 Q2	$422K	Hold	29,984	–	–	0.29%	27
2022 Q1	$726K	Sell	29,984 -5,051	-14%	-$122K	0.34%	26
2021 Q4	$818K	Buy	+35,035	New	+$705K	0.24%	29

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Nan Fung Group Holdings's ACAD Position: Q2 2026 in Review

Nan Fung Group Holdings held its Acadia Pharmaceuticals (ACAD) position steady in Q2 2026 at 102,984 shares worth $2.61M. The position accounts for 1.98% of the portfolio, ranked #14.

Nan Fung Group Holdings first reported a position in ACAD in Q4 2021 and has held it in 19 quarters since. The position peaked at $2.75M in Q4 2025. 352 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

Nan Fung Group Holdings held 102,984 shares of Acadia Pharmaceuticals worth $2.61M as of Q2 2026.
Nan Fung Group Holdings left its Acadia Pharmaceuticals share count unchanged in Q2 2026.
Acadia Pharmaceuticals made up 1.98% of Nan Fung Group Holdings's portfolio in Q2 2026, its #14 holding.
Nan Fung Group Holdings first reported a position in Acadia Pharmaceuticals in Q4 2021 and has held it in 19 quarters since.
Nan Fung Group Holdings's Acadia Pharmaceuticals position peaked at $2.75M in Q4 2025.
352 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Nan Fung Group Holdings's 13F filing for Q2 2026, filed 13 Aug 2026.